Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences in November
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in the Jefferies Global Healthcare Conference in June
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Upcoming Investor Conference in April
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in TD Cowen 45th Annual Health Care Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.